Lunch workshop at the American Association for the Advancement of Science (AAAS) Annual Meeting

WHY:

The advent of biologics (protein-based medications) has benefited countless patients with chronic diseases – including cancer, anemia, diabetes, rheumatoid arthritis, psoriasis and multiple sclerosis.

However, there has been an unexpected consequence: the development of NAbs, in which the body perceives protein-based therapies to be foreign and mounts an immune response against them. As treatment with biologics increases, the hot debate continues about whether NAbs are just innocent immunological bystanders or a natural defense mechanism that diminishes the efficacy of biologic therapies. Professionals need expert synthesis and consensus.

This program will outline in workshop style how a consensus was developed by the CMSC, the leading professional association in multiple sclerosis care.

WHO:

Frederick Munschauer, MD, Chair, Department of Neurology, SUNY at Buffalo School of Medicine and Chief, The Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, New York; Secretary of the Board of Governors, CMSC, and the Co-Chair of the CMSC Cooperative Studies Group in Multiple Sclerosis

Andrew R. Pachner, MD, Professor of Neurology and Neurosciences, Department of Neurosciences, University of Medicine & Dentistry of New Jersey, Newark, New Jersey

WHEN:

Saturday, February 14, 2004
12–1:30 p.m.

WHERE:

Convention Center Exhibit Hall 4C, Workshop Room D
Washington State Convention & Trade Center
800 Convention Place
Seattle, WA

CONTACT:

Cindy Gessell 201-652-4778 or Amy Losak 646-935-3917

This workshop is sponsored by the Consortium of Multiple Sclerosis Centers (CMSC)